---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-037397"
form_type: "8-K"
ticker: "CGTX"
cik: "0001455365"
company_name: "COGNITION THERAPEUTICS INC"
filed_at: "2023-03-28T23:59:59+00:00"
generated_at: "2026-06-17T12:35:44.323085+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Cognition Therapeutics reports CT1812 alters Alzheimer's disease biomarkers in meta-analysis of 24 patients

## Summary
- Meta-analysis of 24 participants (SHINE-A) and full SPARC dataset showed CT1812 significantly alters 28 biomarkers.
- 11 of 28 biomarkers are priority Alzheimer's targets; effects seen on clusterin (CLU) and prion protein (PRPN).
- Pathways affected include synapse health, neuroinflammation, and amyloid-β biology, consistent with mechanism.
- Data presented at AD/PD 2023 conference; management says findings strengthen understanding of CT1812's effect on Aβ oligomer-driven neurotoxicity.
- Ongoing trials expected to read out in coming months.

## SEC filing metadata
- accession: 0001104659-23-037397
- form_type: 8-K
- ticker: CGTX
- cik: 0001455365
- company_name: COGNITION THERAPEUTICS INC
- filed_at: 2023-03-28T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1455365/000110465923037397/0001104659-23-037397-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1455365/000110465923037397/tm2310682d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-037397
- JSON: https://secwatch.observer/filing/0001104659-23-037397.json
- Plain text: https://secwatch.observer/filing/0001104659-23-037397.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.